Latest1 information on COVID-19
©2022 Stanford Medicine
Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
Recruiting
I'm InterestedTrial ID: NCT04120311
Purpose
This phase I trial will assess primarily the safety and secondarily anti-inflammatory effect
of Episcleral Dexamethasone in patients suffering from macular edema and other disorders of
the retina, choroid and vitreous.
Official Title
Phase I Study of Sequestered Transscleral, Controlled-Release Dexamethasone Delivered Via Episcleral Reservoir for Treatment of Macular Edema & Inflammatory Disorders of the Eye Posterior Pole Including Sclera, Choroid, Retina or Vitreous
Stanford Investigator(s)
Theodore Leng, MD, FACS
Associate Professor of Ophthalmology and, by courtesy, of Anesthesiology, Perioperative and Pain Medicine (Adult MSD)
Eligibility
Inclusion Criteria:
- Age >= 18 years;
- Visual acuity letter score in study eye < 70 and ≥ 25 letters (approximate Snellen
equivalent 20/32 to 20/320);
- Ophthalmoscopic evidence of center-involved macular edema, within the central subfield
(CSF);
- Inflammatory disorders of the sclera, choroid, retina or vitreous
Exclusion Criteria:
- Inability to understand informed consent, cooperate with testing or return to follow
up visits;
- Pregnant or lactating women;
- Co-existent ocular disorder of the cornea, lens or media that will interfere with
assessment of safety or efficacy.
Intervention(s):
drug: Episcleral Dexamethasone
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Amy Dennis, RN
650-497-7935